COMPLEX SETS OF MIRNAS AS NON-INVASIVE BIOMARKERS FOR PSORIASIS
The present invention relates to non-invasive methods, kits and means for diagnosing and/or prognosing of psoriasis in a body fluid sample from a subject. Further, the present invention relates to set of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of psoriasis in a body fluid sample from a subject. In addition, the present invention relates to sets of miRNAs for diagnosing and/or prognosing of psoriasis in a body fluid sample from a subject.
1 . A method for diagnosing and/or prognosing of psoriasis comprising the steps of:
(i) determining an expression profile of a set comprising at least two miRNAs representative thr psoriasis in a blood sample from a subject, and
(ii) comparing said expression profile to a reference, wherein the comparison of said expression profile to said reference allows for the diagnosis and/or prognosis of psoriasis,
wherein the nucleotide sequences of the miRNAs comprised in the set are selected from the group consisting of SEQ ID NO 1 to 283, a fragment thereof, and a sequence having at least 80% sequence identity thereto.
2 . The method of claim 1 , wherein the blood sample is a blood cell sample.
3 . The method of claim 1 , wherein the blood sample is selected from whole blood, PBMC, serum, plasma, a leukocyte sample, a blood cell sample, a leukocyte-, erythrocyte- and/or platelet-containing sample.
4 . The method of claim 2 , wherein the set of miRNAs comprises at least one of the sets of miRNAs listed in FIG. 2 .
5 . The method of claim 2 , wherein the set of miRNAs comprises at least one up-regulated miRNA listed in FIG. 4 a or 4 b and/or at least one down-regulated miRNA listed in FIG. 5 a or 5 b.
6 .- 13 . (canceled)
14 . A kit for diagnosing and/or prognosing of psoriasis comprising
(i) means for determining an expression profile of a set comprising at least two miRNAs representative for psoriasis in a blood sample from a subject, and
(ii) at least one reference.
wherein the nucleotide sequences of said miRNAs are selected from the group consisting of SEQ ID NO: 1 to 283, a fragment thereof, and a sequence having at least 80% sequence identity thereto.
15 . The kit of claim 14 , wherein said means comprise:
(i) a set of at least two polynucleotides or a set of at least two primer pairs for detecting a set comprising at least two miRNAs and for diagnosing and/or prognosing of psoriasis in a blood sample from a subject, wherein the nucleotide sequences of the miRNAs comprised in the set are selected from the group consisting of SEQ ID NO: 1 to 283, and
(ii) a biochip, a RT-PCT system, a PCR-system, a flow cytometer or a next generation
16 .- 21 . (canceled)
22 . The method of claim 2 , wherein the blood cell sample includes erythrocytes, leukocytes, thrombocytes.
23 . The kit of claim 15 , wherein the reference is determined from reference expression profiles of at least 2 control subjects with at least 2 clinical conditions, from which at least one is psoriasis.
24 . The kit of claim 23 , wherein the reference is determined in the same type of blood sample as the subject to be diagnosed and/or prognosed.